Prognostic Factors in Patients with Triple Negative Breast Cancer Undergoing Adjuvant Radiotherapy: A 10-Year Single Center Experience Triple negative breast cancer

Main Article Content

Berrin Benli Yavuz
Meryem Aktan
Gul Kanyilmaz


triple negative breast cancer, survival, prognosis, radiotherapy


Background: Triple negative breast cancer (TNBC) is the most aggressive and worst prognosis group among breast cancer molecular subtypes. Determining the prognostic factors and parameters affecting survival in the TNBC group were aimed with this retrospective study.

Methods: The patients were divided into two groups as TNBC and non-TNBC. Clinicopathological and treatment parameters of both groups were compared. Survival rates were evaluated using Kaplan Meirer method.

Results: 110(11.1%) of 992 patients were triple negative. 2, 5 and 10-year overall survival (OS) was 91.8%, 75.8%, 64% and 98.5%, 91.3% and 76.2%, respectively in the TNBC and non-TNBC groups. Disease-free survival (DFS) was median 29.7 months in the TNBC group and 52.37 months in the non-TNBC group. The TNBC group has more grade 2-3 tumors (95.8% vs 87.8%, p=0.019), higher ki-67 value (72.7% vs 44.9%, p<0.001), more metastasis presence (28.2% vs 16.2%, p=0.002) and more exitus (28.2% vs 14.5%, p<0.001) than the non-TNBC group. It was not statistically significant as well as local recurrence was higher in the TNBC group. Brain metastasis was observed more frequently in the TNBC group. In the TNBC group, being ≥70 years of age (p=0.05), having T3-4 disease (p=0.040), presence of PNI (p=0.022), presence of metastasis (p<0.001), presence of brain metastasis (p=0.049) had a negative effect on OS in univariate analysis.

Conclusion: Shorter OS and DFS were found in the TNBC group similar to previous studies. Since hormonal treatment cannot be used in this group, individualization of treatments gains importance by knowing the prognostic factors.   


Breast cancer (BC) is the most common type of cancer in women in the world, and it is the 2 nd most common cause of cancer-related deaths. 1 Breast cancer is a heterogeneous disease and is divided into 4 molecular groups: Luminal A, Luminal B, human epidermal growth factor receptor-2 (HER-2) positive and triple negative subtypes according to hormone receptor status. 2 Triple negative breast cancer (TNBC) consists of subgroups in which estrogen receptor (ER) and progesterone receptor (PR) stain less than <1% and HER-2 is negative. 3 TNBC accounts for approximately 10-15% of all breast cancers. 45 The risk of TNBC increases with young menarche, young first birth, non-breastfeeding, and abdominal obesity. 6 It is more common in young women, obese people and BRCA-1 carriers. 7 TNBC is a heterogeneous group and has at least six different genetic subtypes. 8 It has a histopatho-logically high grade, increased mitotic activity, a high nuclear cytoplasmic ratio and an accelerated tumor proliferation rate. 6 We observe a larger tumor size 1 , less nodal involvement, 7 more distant metastasis, 6 poor prognosis, 9 and increased mortality, 4 in this group of patients. It was observed that distant metastases are more common three years after the diagnosis, 10 and lung and that brain metastases are more common than bone metastases. 116 Mortality rates in the first 5 years after diagnosis are 40%. 10 Their 5-year survival rate is less than the subtype with the best prognosis at 8-16%. 6 Treatment approaches in TNBC include surgery, radiotherapy (RT) and chemotherapy (CT). Surgery may be in the form of mastectomy or lumpectomy. 7 Standard systemic treatment is still anthracycline and taxane-containing chemotherapy regimens. 12 TNBC responds well to neoadjuvant CT (NAC) and the results have been found to be better in patients who a show complete pathological response. Capecitabine is often used as an adjuvant therapy in groups who do not show a complete pathological response. 13 The difficulty in treatment management is the absence of hormonal and target treatments in this group of patients. 14 Adjuvant RT plays an important role in BC. RT is applied after breast protective surgery (BCS), chest wall+/-regional nodal irradiation in high-risk patients after mastectomy, recurrence of disease and palliative purposes in metastasis. 11 RT reduces local recurrence and overall mortality. 2 EBCTCG (Early Breast Cancer Trialists' Collaborative Group) meta-analysis revealed that 10-year locoregional recurrence (LRR) and 20-year breast cancer mortality decreased with postmastectomy RT (PMRT) in patients with 1-3 lymph node positivity. 14 PMRT is recommended for patients whose 1-3 or 4 and more lymph nodes are positive in the National Comprehensive Cancer Network's clinical practice guideline. 15 However, RT is not recommended according to molecular subtypes in studies and NCCN guidelines.

We observed in our clinical practice that TNBC patients progress faster and survival is lower despite all treatments. Therefore, with respective study, we aimed to show patients and treatment characteristics and survival differences between TNBC and non-TNBC in patients undergoing adjuvant radiotherapy in our clinic.


Patient selection

Nine hundred ninety-six patients who underwent curative radiotherapy between January 2010 and November 2020 in our clinic were included in the study. Female patients over 18 years of age with pathologically invasive tumors and at least 12 months follow-up were included in the study. Patients with bilateral breast cancer, metastatic disease, a second malignancy, and male patients were not included. Patients data and treatment characteristics were obtained from medical records and the hospital system. Patients were classified according to American Joint Committee on Cancer (AJCC), Version 8. 16 The patients receiving neoadjuvant therapy were staged according to the pre-treatment imaging methods, and the patients receiving adjuvant therapy according were staged to the postoperative pathology data and preoperative imaging.

ER and PR status and HER-2 were evaluated immunohistochemically. If ER and PR were below 1%, they were accepted as negative. HER-2 was considered negative if 1(+) in IHC and positive if 3(+). HER-2 amplification was evaluated by fluorescence in situ hybridization (FISH) method in the two (+) group. Breast cancer subtypes were grouped as luminal A (ER/PR (+), HER-2 (-)), luminal B (ER/PR (+), HER-2 (+)), HER-2 (+) (ER/PR (-), HER-2 (+)) and triple negative (ER/PR/HER-2 (-)) according to the hormone status in IHC. The patients were categorized into two groups as TNBC and non-TNBC. Patients and tumor characteristics of both groups were obtained from the records. Clinicopathological characteristics of the patients (histological type, stage, tumor size, lymph node involvement, grade, perineural invasion (PNI), lymphovascular invasion (LVI), extracapsular invasion (ECE), ER/PR/HER-2 status, ki-67), and treatments (type of surgery, chemotherapy, radiotherapy) were evaluated separately for both groups. Ethics committee approval was obtained before starting the study. The principles in the latest version of the Helsinki Declaration were followed. No informed consent was obtained from the patients due to the retrospective nature of the study.


Patients underwent BCS or modified radical mastectomy (MRM), sentinel lymph node dissection (SLND) or axillary dissection. Chemotherapy was administered as adjuvant or neoadjuvant in the form of 4 cycles of cyclophosphamide and adriamycin +/-12 weeks or 4 cycles of taxanes. Radiotherapy was administered in the presence of T3-4, lymph node involvement, LVI, PNI, ECE after MRM. After BCS, adjuvant RT was given to all of the patients. Nodal irradiation was performed in those who were node positive. Nodal irradiation was administered to the axillary and supraclavicular region. Mammary interna lymphatics were included in the treatment area if the number of involved lymph nodes was large and mammary interna lymph nodes were positive in tumors located in the inner and middle quadrant. Treatment was administered using a 3D conformal technique and the standard two parallel opposing tangential field technique. Then, 50 Gy RT was applied to the chest wall/ breast tissue of the patients. A boost was added to the 10-16 Gy tumor bed in patients who underwent BCS. All patients were treated with Eclipse treatment planning system (Varian Medical Systems Inc. Palo Alto, CA). No treatment was planned as part of the protocol of this study.

Survival Analysis

The primary endpoint of the study was to found the survival differences between the TNBC and non-TNBC groups. The secondary aim was to find the prognostic factors affecting overall survival (OS) and disease-free survival (DFS). OS was defined as the time from the date of diagnosis to death or last control. DFS was defined as the time from the date of diagnosis to the date of the first occurrence of metastasis/local-regional recurrence /death.

The patients were followed up retrospectively from the records until March 2022 or death. During this period, they were routinely followed up once every 3 months for the first 2 years, once every 6 months for up to 5 years, and then once a year.


The patients' characteristics were summarized as n (%) for categorical variables and continuous variables as median. Patients and tumor characteristics in both groups were evaluated by chisquare test and Mann Whitney u test. Survival rates were evaluated using the Kaplan Meirer method. Survival differences between the two groups were evaluated using the log-rank test. All statistical survival analyses were performed using SAS University Edition 9.4 program. The First's correction was used in multivariable cox regression. P<0.05 was considered statistically to be significant.


Patient and treatment characteristics

One hundred ten (11.1%) of the 992 patients were triple negative. The median age was 50 (27-87) and 50 (27-83) in the TNBC and non-TNBC groups, respectively. The median follow-up was 73.57 months (12.32-153.49). Also, 47.4% of our patients were postmenopausal. The characteristics of the patients and the treatments are summarized in Table1 and Table 2. The most common histology in the TNBC group was invasive ductal carcinoma (74.5%). The medullary carcinoma subtype was observed more frequently than non-TNBC group. The TNBC group had more grade 2-3 tumors (95.8% vs 87.8%, P=0.019), a higher ki-67 value (72.7% vs 44.9%, P<0.001), more metastasis presence (28.2% vs 16.2%, P=0.002) and more exitus (28.2% vs 14.5%, P<0.001) than the non-TNBC group. Also, local recurrence was higher in the TNBC group, although it was not statistically significant. When the patients with metastases were evaluated, visceral and bone metastases were not different between the groups, while brain metastases were observed to be more common in the TNBC group (51.6% vs 21.7%, P=0.001) ( Table-3).


During the median follow-up of 73.57 months, 883 of 992 patients (84%) were alive and 174 of 992 (17.5%) had distant metastasis. While t h e mean survival r a t e was 131.978 months in the whole group, it was 117.7 and 132.2 months in the TNBC and non-TNBC groups, respectively. In addition, 2, 5 and 10-year overall survival (OS) was 91.8%, 75.8%, 64% and 98.5%, 91.3% and 76.2%, respectively in the TNBC and non-TNBC groups (Figure-1). The median of DFS was 52.37 months in the non-TNBC group while it was 29.7 months in the TNBC group. Additionally, 2, 5 and 10-year DFS were 65.3%, 27.3%, 0% and 78.4%, 44.3% and 3.2%, respectively ( Figure-1).

When evaluated as a whole group, factors like receiving neoadjuvant CT (P<0.001), suffering from TNBC (P<0.001), being ≥70 years of age (p<0.001), being postmenopausal (P=0.010), having grade 2-3 (P=0.019), having ki-67>20 (P=0.014), having the T3-4 disease (P<0.001), having the N2-3 disease (P<0.001), the presence of ECE (P<0.001), the presence of PNI (P=0.014), the presence of LVI (P<0.001), the presence of metastasis (P<0.001), the presence of brain (P<0.001) and visceral (P=0.011) metastasis and the presence of local regional recurrence (P=0.004) were found to have a negative effect on OS in univariate analyses. Receiving neoadjuvant CT (P=0.017), having the N2-3 disease (P=0.026), and the presence of ECE (P=0.049) had a negative effect on DFS.

No effect on DFS was found while f a c t o r s l i ke being ≥70 years of age (P=0.05), having t he T3-4 disease (P=0.040), the presence of PNI (P=0.022), the presence of metastasis (P<0.001), and the presence of brain metastasis (P=0.049) had a negative effect on OS in univariate analysis in the TNBC group (Table 4). In the non-TNBC group, receiving neoadjuvant CT (P=0.001), being ≥70 years old (P<0.001), being postmenopausal (P=0.002), having a grade 2-3 disease (p=0.026), having the T3-4 disease (P<0.001), the having N2-3 disease (P<0.001), the presence of ECE (P<0.001), the presence of LVI (P<0.001), the presence of metastasis (P<0.001), the presence of brain (P<0.001) and visceral (P=0.014) metastasis and the presence of local regional recurrence (P=0.021) were found to have a negative effect on OS (Table 4). When evaluated in terms of DFS, having t h e N2-3 disease (P=0.026) had a negative effect on the results of univariate analysis.

In the results of multivariate analysis, suffering from TNBC, having the N2-3 disease, being ≥70 years old, being postmenopausal, and the presence of metastasis were found to be factors affecting OS negatively in the whole group. Being ≥70 years old, suffering from TNBC, having the T3-4 disease, and having the N2-3 disease were independent prognostic factors for DFS (Table 5). 17 Today, not only the TNM stage but also the hormone status are effective in the process of deciding on the treatment of this global problem. TNBC, on the other hand, is difficult to manage because hormonal and target treatments cannot be administered.

Improved demonstration of clinicopathological and prognostic factors is important in terms of treatment planning in this group. The TNBC and non-TNBC groups were compared over 10 years in this retrospective study. In our clinic, 11.1% of breast cancers treated for curative purposes in the last 10 years had triple negative histology, showing that mortality and metastasis rates were worse in the TNBC group than in the non-TNBC group. The majority of the patients had invasive ductal carcinoma. They had a higher-grade cancer and higher Ki-67 values. TNBC is a subgroup associated with poor prognosis, and high recurrence rates in the first 3 years and higher mortality rates in the first 5 years. 2 In previous research, 5-year OS and DFS were found to be 75.8% and 27.3% in the TNBC group, and 91.3% and 44.3% in the non-TNBC group, in accordance with the literature in our data. Having TNBC was determined as an independent variable that negatively affected both OS and DFS in multivariate analysis results. The risk of death in those with triple negative disease was found to be 1.8 times higher than in the other group (HR: 1.8, 95%, Cl: 1.2-2.7, P=0.0044). Nodal status is one of the most important prognostic factors in BC. In some studies, nodal disease was found to be a prognostic factor in TNBC patients. 18 In our study, the N2-3 disease had a negative effect on OS in both TNBC and non-TNBC groups. Also, in multivariate analysis, having the N2-3 disease had a negative effect on OS and DFS. The risk of death has been found to increase 1.6 times in those who have the N2-3 disease (HR: 1.6, 95, Cl%: 1.1-2.3, P=0.0049).

Lymph node involvement was less common compared to the non-TNBC group (55.2% vs 65.4%, P=0.041). The poor prognosis in the TNBC group is thought to be due to hematogenous metastasis rather than lymph node metastasis. 11 The brain metastasis was observed more frequently in TNBC, while no difference was observed between the groups in visceral organ metastasis and bone metastases in our study.

In our study, the rate of local recurrence was 3.6%. In another study examining 2007 TNBC patients, local recurrence and distant metastasis were found to be 31.9% and 51.4%, respectively, after 10 years of observation, and the rate of brain metastasis was 9.6%. 4 However, it is thought that stage IV patients who received radiotherapy in 50.4% of the case group in this study showed increased local recurrence rates. In a meta-analysis including studies, it was shown that recurrence and general mortality decreased with RT in 1 -3, 4 or more node-positive patients. In node-negative patients, locoregional recurrence occurred in 16% of nonirradiated women before distant metastasis. RT reduced local recurrences but was not found to be effective in overall mortality and breast cancer mortality in this group. 14 In the Danish breast cancer group study, TNBC was found to be associated with increased overall mortality and distant metastasis, but this effect could not be observed in patients who underwent postmastectomy RT. Locoregional recurrence (LRR) was significantly increased in TNBC. 19 As the rate was 5% in the TNBC group and 2-3% in the hormone-positive group at 10 years after LRR, BCS and RT administration in early-stage BC. 20 Thanks to neoadjuvant chemotherapy, the surgeons select breast-conserving surgery for a group of patients that were previously the candidate of total mastectomy. 15 Even if it is an operable disease, it is accepted as the standard approach in TNBC and HER-2 positive patients. If the pathological complete response is detected, significantly better DFS and OS are seen. 20 In our cases, NAC was administered to 10.9% of the TNBC group and 8.7% of the non-TNBC group. NAC administration was found to have a negative effect on OS and DFS in the whole group and on OS in the non-TNBC group. It was also negative in the whole group and non-TNBC group in the multivariate analysis results. Pathological complete response (pCR) occurred in 24.7% of patients receiving NAC. There was no statistical difference between the TNBC and non-TNBC groups (41.7% vs 22.1%, P=0.143). All patients receiving NAC had 2 nd and 3 rd stage diseases. The early-stage patients are usually treated with the first surgery in our hospital, and patients receiving NAC treatment are more frequently advanced stage patients. Besides, the NAC plan is not administered independently of the stage according to the hormone receptor status. The negative effect of NAC on OS and DFS is thought to be due to this.

Ki-67 is commonly used to evaluate the proliferative index in BC. 21 Cut-off values for Ki-67 vary in the literature. In the study carried on 1800 TNBC patients, Zhu et al. showed that Ki-67 was above 20% in 84.39% of the patients. Ki-67 values were found to be higher in TNBC than the luminal cancers. Shorter OS and DFS were shown in patients with Ki-67 values higher than 30%. 22 In our study, the median ki-67 value was 20 (range: 1-95). Similar to the literature, the high ki-67 value was more in the TNBC group compared to the non-TNBC group (72.7% vs 44.9%, p<0.001). The high Ki-67 levels in the whole group had a negative effect on OS in the univariate analysis.

The limitation of our study was its retrospective nature and partially the small number of patients. It is known that TNBC is more common in patients with BRCA mutation. 7 However, we did not know about BRCA mutations in this study. The strength of the study, on the other hand, was that since all patients treated in our clinic were evaluated, selection bias was minimal. All patients were treated in the same center with the same treatment protocols. Also, the median follow-up was 73.57 months.


This single-center study showed that having TNBC had a negative impact on OS and DFS. The TNBC group had more grade 2-3 tumors, higher ki-67 values, more metastasis, and more exitus than the non-TNBC group. The treatment in TNBC patients should be determined by considering all factors affecting recurrence and survival and individualizing.


Ethics committee of the institution has approved the protocol of the study before starting FUNDING This research received no specific grant from any funding agency in the public, commercial, or not-forprofit sectors.


There are no conflicts of interest to be declared by the authors.

Overall survival curves in TNBC (a) and non-TNBC groups (b).

Characteristics of the patients and tumors Characteristics TNBC N (%) Non-TNBC N (%) P value Patients Age (median) Menopausal status Premenopausal Postmenapausal Stage Stage I-II Stage III Nx Tumor stages T0-1-2 T3-4 Lymph node stages N0-1 N2-3 Pathology Ductal Lobular Mixt Medullar Others Grade Grade 1 Grade 2-3 ECE Yes No PNI Yes No LVI Yes No Ki-67 ≤20 >20 110 (11.1) 50 (27-87) 59 (53.6) 51 (46.4) 63(57.3) 41(37.3) 6(5.5) 87 (79.1) 23 (20.9) 67 (65) 36 (35) 82 (74.5) 2 (1.8) 4 (3.6) 20 (18.2) 2 (1.8) 4 (4.2) 92 (95.8) 29 (33) 59 (67) 25 (27.5) 66 (72.5) 38 (41.8) 53 (58.2) 15 (27.3) 40 (72.7) 882 (88.9) 50 (27-83) 463 (52.5) 419 (47.5) 529(60) 304(34.5) 49(5.6) 735 (83.3) 147 (16.7) 581 (69.5) 255 (30.5) 727 (82.4) 63 (7.1) 30 (3.4) 11 (1.2) 51 (5.8) 97 (12.2) 699 (87.8) 271 (37.5) 452 (62.5) 243 (31.7) 524 (68.3) 382 (49.4) 391 (50.6) 295 (55.1) 240 (44.9) 0.340 0.821 0.842 0.266 0.357 <0.001 * 0.019 * 0.406 0.413 0.167 <0.001 * ECE: extracapsular extension, LVI: lymphovascular invasion, PNI: perineural invasion * statistically significant DISCUSSION According to 2020 GLOBOCAN data, 2.3 million new cases each year (11.7% of all cancers) are expected to have BC.
Factors affecting overall survival in univariate analysis
Factors affecting overall survival and disease-free survival in multivariate analysis


1. Li Y, Zhang N, Zhang H, Yang Q. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma. J Clin Pathol. 2019;72(6):418-424. doi: 10.1136/jclinpath-2018-205544.
2. Zhang J, Wang XX, Lian JY, Song CG. Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database. Oncotarget. 2019;10(50):5245-5252. doi:10.18632/oncotarget.24703.
3. Soares RF, Garcia AR, Monteiro AR, Macedo F, Pereira TC, Carvalho JC, et al. Prognostic factors for early relapse in non-metastatic triple negative breast cancer - real world data. Rep Pract Oncol Radiother. 2021;26(4):563-572. doi: 10.5603/RPOR.a2021.0073.
4. De-la-Cruz-Ku G, Luyo M, Morante Z, Enriquez D, Möller MG, Chambergo-Michilot D, et al. Triplenegative breast cancer in Peru: 2000 patients and 15 years of experience. PLoS One. 2020;15(8):e0237811. doi: 10.1371/journal.pone.0237811.
5. Zhang L, Tang R, Deng JP, Zhang WW, Lin HX, Wu SG, He ZY. The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer. BMC Cancer. 2020;20(1):1146. doi: 10.1186/s12885-020-07639-x.
6. Jitariu AA, Cîmpean AM, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death. Oncotarget. 2017;8(28):46652-46662. doi: 10.18632/oncotarget.16938.
7. Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, et al. Triple negative breast cancer in Asia: An insider's view. Cancer Treat Rev. 2018;62:29-38. doi: 10.1016/j.ctrv.2017.10.014.
8. James M, Dixit A, Robinson B, Frampton C, Davey V. Outcomes for Patients with Non-metastatic Triplenegative Breast Cancer in New Zealand. Clin Oncol (R Coll Radiol). 2019;31(1):17-24. doi: 10.1016/j.clon.2018.09.006.
9. Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136-145. doi: 10.1016/j.semcancer.2020.06.005.
10. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi: 10.1186/s13058-020-01296-5.
11. He MY, Rancoule C, Rehailia-Blanchard A, Espenel S, Trone JC, Bernichon E, et al. Radiotherapy in triple negative breast cancer: Current situation and upcoming strategies. Crit Rev Oncol Hematol. 2018;131:96-101. doi: 10.1016/j.critrevonc.2018.09.004.
12. Tufano AM, Teplinsky E, Landry CA. Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer. Clin Breast Cancer. 2021;21(1):1-9. doi: 10.1016/j.clbc.2020.07.001.
13. Tečić Vuger A, Šeparović R, Vazdar L, Pavlović M, Lepetić P, Šitić S, et al. Characteristics and prognosis of triple-negative breast cancer patients: A Croatian single institution retrospective cohort study. Acta Clin Croat. 2020;59(1):97-108. doi: 10.20471/acc.2020.59.01.12.
14. Yao Y, Chu Y, Xu B, Hu Q, Song Q. Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Med. 2019;8(2):554-563. doi: 10.1002/cam4.1954.
15. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127-35. Erratum in: Lancet. 2014 Nov 22;384(9957):1848. doi: 10.1016/S0140-6736(14)60488-8.
16. NCCN clinical practice guidelines in oncology: breast cancer, version 2 National Comprehensive Cancer Network 2022
17. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. (Eds.). AJCC Cancer Staging Manual (8th edition). Springer; 2017:589-628
18. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.
19. Wen S, Manuel L, Doolan M, Westhuyzen J, Shakespeare TP, Aherne NJ. Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients. Breast Cancer (Dove Med Press). 2020;12: 27-35. doi: 10.2147/BCTT.S236483.
20. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(9):1419-26. doi: 10.1200/JCO.2007.14.5565.
21. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet.2021;397(10286):1750-1769 Erratum in: Lancet. 2021 May 8;397(10286):1710. doi: 10.1016/S0140-6736(20)32381-3.
22. Hashmi AA, Hashmi KA, Irfan M, Khan SM, EdhiMM, Ali JP, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019;12(1):605. doi: 10.1186/s13104-019-4653-x.
23. Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020 Jan 14;10(1):225. doi: 10.1038/s41598-019-57094-3.

Article Statistics :Views : 4195 | Downloads : 257 : 67